These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25338498)

  • 1. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
    Wick W; Fricke H; Junge K; Kobyakov G; Martens T; Heese O; Wiestler B; Schliesser MG; von Deimling A; Pichler J; Vetlova E; Harting I; Debus J; Hartmann C; Kunz C; Platten M; Bendszus M; Combs SE
    Clin Cancer Res; 2014 Dec; 20(24):6304-13. PubMed ID: 25338498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
    Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
    Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients.
    Tuettenberg J; Seiz M; Debatin KM; Hollburg W; von Staden M; Thiemann M; Hareng B; Fricke H; Kunz C
    Int Immunopharmacol; 2012 May; 13(1):93-100. PubMed ID: 22446296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
    Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
    Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
    Boch T; Luft T; Metzgeroth G; Mossner M; Jann JC; Nowak D; Meir F; Schumann C; Klemmer J; Brendel S; Fricke H; Kunz C; Weiß C; Hofmann WK; Nolte F
    Leuk Res; 2018 May; 68():62-69. PubMed ID: 29549809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.
    Wick W; Krendyukov A; Junge K; Höger T; Fricke H
    J Neurooncol; 2019 Dec; 145(3):531-540. PubMed ID: 31679112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.
    Raimbault A; Pierre-Eugene C; Rouquette A; Deudon C; Willems L; Chapuis N; Mathis S; Kunz C; Fricke H; Kosmider O; Bardet V; Fontenay M;
    Oncotarget; 2016 Mar; 7(12):14898-911. PubMed ID: 26910909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
    Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
    Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
    Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.
    Grabenbauer GG; Gerber KD; Ganslandt O; Richter A; Klautke G; Birkmann J; Meyer M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):164-9. PubMed ID: 19695435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
    Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
    J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
    Wick W; Gorlia T; Bady P; Platten M; van den Bent MJ; Taphoorn MJ; Steuve J; Brandes AA; Hamou MF; Wick A; Kosch M; Weller M; Stupp R; Roth P; Golfinopoulos V; Frenel JS; Campone M; Ricard D; Marosi C; Villa S; Weyerbrock A; Hopkins K; Homicsko K; Lhermitte B; Pesce G; Hegi ME
    Clin Cancer Res; 2016 Oct; 22(19):4797-4806. PubMed ID: 27143690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.
    Colman H; Berkey BA; Maor MH; Groves MD; Schultz CJ; Vermeulen S; Nelson DF; Mehta MP; Yung WK;
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):818-24. PubMed ID: 16887285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
    Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
    J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.